An update on recent developments and highlights in food allergy

Locke, Arielle; Hung, Lisa; Upton, Julia; O’Mahony, Liam; Hoang, Jennifer; Eiwegger, Thomas

doi:10.22541/au.167660670.04711345/v1

Cited by 3 publications

(2 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sequential epitope‐specific IgE‐profiling appears valuable in the course of immunotherapy, such as sublingual (SLIT), subcutaneous (SCIT) and peanut oral immunotherapy (OIT) 19,20 . Lower sIgE to food allergens at baseline was related to increased efficacy of peanut OIT 21 . Allergen provocation testing is the gold standard when clinical history is inconclusive 22 …”

Section: Allergy: Current and Emerging Biomarkers And Therapeutic App...mentioning

confidence: 99%

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

Turner,

Radzikowska,

Ferastraoaru

et al. 2024

Allergy

View full text Add to dashboard Cite

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE‐mediated diseases and glioma. Allergic disease stems from a Th2‐biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour‐immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro‐Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult‐type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.

show abstract

Section: Allergy: Current and Emerging Biomarkers And Therapeutic App...mentioning

confidence: 99%

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

Turner,

Radzikowska,

Ferastraoaru

et al. 2024

Allergy

View full text Add to dashboard Cite

show abstract

“…19,20 Lower sIgE to food allergens at baseline was related to increased efficacy of peanut OIT. 21 Allergen provocation testing is the gold standard when clinical history is inconclusive. 22 Indirect sIgE-detection can be performed with a flow cytometrybased functional assay that measures basophil activation after allergen exposure (basophil activation test, BAT).…”

Section: F I G U R Ementioning

confidence: 99%

AllergoOncology: Biomarkers and Refined Classification for Research in the Allergy and Glioma Nexus - a Joint EAACI-EANO Position Paper

Poli,

Turner,

Radzikowska

et al. 2023

Preprint

View full text Add to dashboard Cite

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype, and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment, and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.

show abstract

Update on In Vitro Diagnostic Tools and Treatments for Food Allergies

Brasal-Prieto,

Fernández-Prades,

Dakhaoui

et al. 2023

Nutrients

View full text Add to dashboard Cite

Food allergy (FA) is an adverse immunological reaction to a specific food that can trigger a wide range of symptoms from mild to life-threatening. This adverse reaction is caused by different immunological mechanisms, such as IgE-mediated, non-IgE-mediated and mixed IgE-mediated reactions. Its epidemiology has had a significant increase in the last decade, more so in developed countries. It is estimated that approximately 2 to 10% of the world’s population has FA and this number appears to be increasing and also affecting more children. The diagnosis can be complex and requires the combination of different tests to establish an accurate diagnosis. However, the treatment of FA is based on avoiding the intake of the specific allergenic food, thus being very difficult at times and also controlling the symptoms in case of accidental exposure. Currently, there are other immunomodulatory treatments such as specific allergen immunotherapy or more innovative treatments that can induce a tolerance response. It is important to mention that research in this field is ongoing and clinical trials are underway to assess the safety and efficacy of these different immunotherapy approaches, new treatment pathways are being used to target and promote the tolerance response. In this review, we describe the new in vitro diagnostic tools and therapeutic treatments to show the latest advances in FA management. We conclude that although significant advances have been made to improve therapies and diagnostic tools for FA, there is an urgent need to standardize both so that, in their totality, they help to improve the management of FA.

show abstract

An update on recent developments and highlights in food allergy

Cited by 3 publications

References 145 publications

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

AllergoOncology: Biomarkers and Refined Classification for Research in the Allergy and Glioma Nexus - a Joint EAACI-EANO Position Paper

Update on In Vitro Diagnostic Tools and Treatments for Food Allergies

Contact Info

Product

Resources

About